Figure 7

Pharmacological inhibition of glycolysis impairs B-ALL proliferation and sensitizes to apoptosis in vitro and in vivo. (a–c) WT B-ALL cells were cultured in low (1 mM) or high (5 mM) dose of 2-DG and (a) cell number was counted and (b) cell viability was analyzed by flow cytometry over time. (c) Cell lysates were analyzed by immunoblot. (d) WT or Bim^−/− B-ALL cells were treated with 5 mM 2-DG and cell viability was analyzed by flow cytometry over time. (e) WT B-ALL cells were adoptively transferred into host animals that were treated starting on day 2 with vehicle alone or with 500 mg/kg per day of 2-DG alone for 4 days or with additional 10 mg/kg per day of Dasatinib for 3 days. GFP+ B-ALL cell percentages and numbers were determined by flow cytometry. Means and S.D. are shown of (a, b and d) triplicate and (e) n=5 mice/group. ****P<0.0001, ***P<0.001, **P<0.005, *P<0.05